BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced financial results for the first quarter ended March 31, 2025.
"During a time when market resource constraints threaten to slow scientific progress, we remain committed to keeping the innovation engine moving forward,” said Masoud Toloue, CEO of Quanterix. "Today, we are excited to announce a major advance: through a new early-access program, Simoa® ONE assay kits will become compatible with over 20,000 existing flow cytometers worldwide—significantly reducing the need for capital equipment purchases by current and future customers. This leap is enabled by a breakthrough in reagent design: Simoa’s digital, ultra-sensitive detection now operates with kinetic dye-encoded beads, dramatically expanding our reach to an installed base more than twenty times the size of our own. We are democratizing access to ultrasensitive biomarker detection by meeting researchers where they are—a major step forward in our mission to bring Simoa to all labs."
Toloue continued, "Following a solid first quarter that exceeded our expectations, we are proactively positioning the company for long-term success. In light of ongoing market headwinds, we are taking a disciplined approach to guidance and implementing targeted cost reductions of approximately $30 million annually. These actions strengthen our path to generate positive cash flow by 2026, reinforce our commitment to sustainable innovation-driven growth, and help to streamline our coming integration with Akoya Biosciences."
First Quarter Financial Highlights
- Revenue of $30.3 million, a decrease of 5% compared to $32.1 million in the prior year.
- GAAP gross margin of 54.1%, as compared to 57.8% in the prior year. Adjusted gross margin (non-GAAP) of 49.7% as compared to 51.2% in the prior year.
- Net loss of $20.5 million, compared to a net loss of $11.2 million in the prior year.
- The Company ended the first quarter with $269.5 million of cash, cash equivalents, marketable securities, and restricted cash, representing a use of cash of approximately $22 million. During the quarter, Quanterix incurred $13.2 million of cash expenses relating to the EMISSION acquisition, Akoya deal expenses and the Company’s previous restatement. Excluding these payments, adjusted cash burn in the quarter was $9.0 million, compared to adjusted cash burn of $19.4 million in the prior year.
Operational and Business Highlights
- ARUP Laboratories, a leading national reference laboratory in the United States announced they will now offer a pTau217 blood test for Alzheimer’s disease using the Quanterix platform and assay kit.
- Received Proprietary Laboratory Analysis (PLA) codes for LucentAD® and LucentAD Complete tests, with pricing expected in the third quarter of 2025.
- Launched a new dried blood spot (DBS) extraction kit, expanding the Simoa assay portfolio with a less invasive, more cost-effective method for detecting low-abundance biomarkers- expanding access to high-sensitivity testing in a broader range of settings
- Amended the merger agreement with Akoya Biosciences, reducing the equity value of the transaction by 67% and increasing Quanterix shareholder ownership from 70% to 84% post-closing. The transaction is expected to close in June 2025.
- Implementing cost reduction initiatives to achieve $30 million in annual savings. This is a first step toward generating positive cash flow by 2026 with a cash balance in excess of $100 million.
2025 Full Year Business Outlook
In assessing recent cuts to academic research funding, biopharma spending patterns, and tariffs, for 2025, on a standalone basis excluding the planned acquisition of Akoya, the Company expects to report revenues in a range of $120 million to $130 million, which represents a year-over-year revenue decline of 5% to 13%. This estimate excludes revenue from Lucent Diagnostics testing. The Company expects GAAP gross margin to be in the range of 55% to 59%, and adjusted gross margin (non-GAAP) in the range of 50% to 54%. Finally, the Company anticipates 2025 adjusted cash burn to be approximately $35.0 million to $45.0 million.
For additional information on the non-GAAP financial measures included in this press release, please see “Use of Non-GAAP Financial Measures” and “Reconciliation of GAAP to Non-GAAP Financial Measures” below.
Conference Call
In conjunction with this announcement, the Company will host a conference call on May 12, 2025, at 4:30 PM E.T. The dial-in number for USA & Canada is Toll-Free (800) 715-9871 or (646) 307-1963 and the conference ID is 7353673.
Interested investors can also listen to the live webcast from the Event Details page in the Investors section of the Quanterix website at https://ir.quanterix.com. An archived webcast replay will be available on the Company’s website for one year.
Financial Highlights
QUANTERIX CORPORATION
|
|||||||
|
Three Months Ended March 31, |
||||||
|
2025 |
|
2024 |
||||
Revenues: |
|
|
|
||||
Product revenue |
$ |
20,739 |
|
|
$ |
19,670 |
|
Service and other revenue |
|
8,763 |
|
|
$ |
11,967 |
|
Collaboration and license revenue |
|
771 |
|
|
$ |
155 |
|
Grant revenue |
|
60 |
|
|
$ |
274 |
|
Total revenues |
|
30,333 |
|
|
|
32,066 |
|
Costs of goods sold and services: |
|
|
|
||||
Cost of product revenue |
|
9,764 |
|
|
$ |
8,237 |
|
Cost of service and other revenue |
|
4,154 |
|
|
$ |
5,281 |
|
Total costs of goods sold and services |
|
13,918 |
|
|
|
13,518 |
|
Gross profit |
|
16,415 |
|
|
|
18,548 |
|
Operating expenses: |
|
|
|
||||
Research and development |
|
10,036 |
|
|
$ |
6,742 |
|
Selling, general and administrative |
|
32,457 |
|
|
$ |
26,039 |
|
Other lease costs |
|
288 |
|
|
$ |
924 |
|
Total operating expenses |
|
42,781 |
|
|
|
33,705 |
|
Loss from operations |
|
(26,366 |
) |
|
|
(15,157 |
) |
Other income (expense): |
|
|
|
||||
Interest income |
|
3,267 |
|
|
|
3,948 |
|
Change in fair value of contingent consideration |
|
(379 |
) |
|
|
— |
|
Other income |
|
61 |
|
|
|
226 |
|
Loss before income taxes |
|
(23,417 |
) |
|
|
(10,983 |
) |
Income tax benefit (expense) |
|
2,913 |
|
|
|
(180 |
) |
Net loss |
$ |
(20,504 |
) |
|
$ |
(11,163 |
) |
|
|
|
|
||||
Net loss per common share, basic and diluted |
$ |
(0.53 |
) |
|
$ |
(0.29 |
) |
|
|
|
|
||||
Weighted-average common shares outstanding, basic and diluted |
|
38,718 |
|
|
|
38,126 |
|
QUANTERIX CORPORATION
|
|||||
|
March 31, 2025 |
|
December 31, 2024 |
||
ASSETS |
|
|
|
||
Current assets: |
|
|
|
||
Cash and cash equivalents |
$ |
76,508 |
|
$ |
56,709 |
Marketable securities |
|
190,369 |
|
$ |
232,413 |
Accounts receivable, net of allowance for expected credit losses |
|
28,258 |
|
$ |
32,141 |
Inventory |
|
31,028 |
|
$ |
32,775 |
Prepaid expenses and other current assets |
|
8,839 |
|
$ |
9,556 |
Total current assets |
|
335,002 |
|
|
363,594 |
Restricted cash |
|
2,639 |
|
$ |
2,610 |
Property and equipment, net |
|
16,457 |
|
$ |
17,150 |
Intangible assets, net |
|
16,520 |
|
$ |
4,031 |
Goodwill |
|
6,574 |
|
$ |
— |
Operating lease right-of-use assets |
|
15,971 |
|
$ |
16,339 |
Other non-current assets |
|
3,349 |
|
$ |
2,809 |
Total assets |
$ |
396,512 |
|
$ |
406,533 |
LIABILITIES AND STOCKHOLDERS' EQUITY |
|
|
|
||
Current liabilities: |
|
|
|
||
Accounts payable |
$ |
6,731 |
|
$ |
6,953 |
Accrued compensation and benefits |
|
6,308 |
|
$ |
12,620 |
Accrued expenses and other current liabilities |
|
13,314 |
|
$ |
8,851 |
Deferred revenue |
|
9,102 |
|
$ |
8,827 |
Operating lease liabilities |
|
4,940 |
|
$ |
4,756 |
Total current liabilities |
|
40,395 |
|
|
42,007 |
Deferred revenue, net of current portion |
|
1,098 |
|
$ |
1,073 |
Operating lease liabilities, net of current portion |
|
31,467 |
|
$ |
32,615 |
Non-current portion of contingent consideration |
|
6,337 |
|
$ |
— |
Other non-current liabilities |
|
822 |
|
$ |
800 |
Total liabilities |
|
80,119 |
|
|
76,495 |
Total stockholders’ equity |
|
316,393 |
|
|
330,038 |
Total liabilities and stockholders’ equity |
$ |
396,512 |
|
$ |
406,533 |
QUANTERIX CORPORATION
|
|||||||
|
Three Months Ended March 31, |
||||||
|
2025 |
|
2024 |
||||
Cash flows from operating activities: |
|
|
|
||||
Net loss |
$ |
(20,504 |
) |
|
$ |
(11,163 |
) |
Adjustments to reconcile net loss to net cash used in operating activities: |
|
|
|
||||
Depreciation and amortization expense |
|
2,188 |
|
|
$ |
1,523 |
|
Credit losses on accounts receivable |
|
53 |
|
|
$ |
73 |
|
Accretion of marketable securities |
|
(979 |
) |
|
|
(1,657 |
) |
Operating lease right-of-use asset amortization |
|
561 |
|
|
|
478 |
|
Stock-based compensation expense |
|
5,462 |
|
|
|
5,265 |
|
Change in fair value of contingent consideration |
|
379 |
|
|
|
— |
|
Other operating activity |
|
(412 |
) |
|
|
55 |
|
Changes in assets and liabilities: |
|
|
|
||||
Accounts receivable |
|
4,329 |
|
|
|
(4,130 |
) |
Inventory |
|
2,085 |
|
|
|
(2,531 |
) |
Prepaid expenses and other current assets |
|
421 |
|
|
|
(281 |
) |
Other non-current assets |
|
(502 |
) |
|
|
(33 |
) |
Accounts payable |
|
399 |
|
|
|
(1,057 |
) |
Accrued compensation and benefits, accrued expenses, and other current liabilities |
|
(3,517 |
) |
|
|
(6,200 |
) |
Deferred revenue |
|
299 |
|
|
|
472 |
|
Operating lease liabilities |
|
(1,157 |
) |
|
|
(988 |
) |
Other non-current liabilities |
|
(2,993 |
) |
|
|
10 |
|
Net cash used in operating activities |
|
(13,888 |
) |
|
|
(20,164 |
) |
Cash flows from investing activities: |
|
|
|
||||
Purchases of marketable securities |
|
(30,246 |
) |
|
|
(137,889 |
) |
Proceeds from sales and maturities of marketable securities |
|
73,261 |
|
|
|
29,200 |
|
Purchases of property and equipment |
|
(1,256 |
) |
|
|
(506 |
) |
Acquisition, net of cash acquired |
|
(8,997 |
) |
|
|
— |
|
Net cash provided by (used in) investing activities |
|
32,762 |
|
|
|
(109,195 |
) |
Cash flows from financing activities: |
|
|
|
||||
Proceeds from common stock issued under stock plans |
|
668 |
|
|
|
2,037 |
|
Payments for employee taxes withheld on stock-based compensation awards |
|
(575 |
) |
|
|
(1,438 |
) |
Net cash provided by financing activities |
|
93 |
|
|
|
599 |
|
Net increase (decrease) in cash, cash equivalents, and restricted cash |
|
18,967 |
|
|
|
(128,760 |
) |
Effect of exchange rate changes on cash, cash equivalents, and restricted cash |
|
861 |
|
|
|
(380 |
) |
Cash, cash equivalents, and restricted cash at beginning of period |
|
59,319 |
|
|
|
177,026 |
|
Cash, cash equivalents, and restricted cash at end of period |
$ |
79,147 |
|
|
$ |
47,886 |
|
Use of Non-GAAP Financial Measures
To supplement our financial statements presented on a U.S. GAAP basis, we present the following non-GAAP financial measures:
- Adjusted EBITDA and adjusted EBITDA margin: We define adjusted EBITDA as net income (loss) adjusted to exclude interest income, income tax (expense) benefit, depreciation and amortization expense, stock-based compensation expense, acquisition and integration related costs, impairment and restructuring, and certain other items which include other charges or benefits resulting from transactions or events that are highly variable, significant in size, and that we do not believe are indicative of ongoing or future business operations. These items are discussed in more detail below the tables reconciling the GAAP to non-GAAP measures. Adjusted EBITDA margin is calculated as adjusted EBITDA divided by total revenues.
- Adjusted gross profit, adjusted gross margin, adjusted total operating expenses, and adjusted loss from operations: We calculate these non-GAAP financial measures by including shipping and handling costs for product sales within cost of product revenue instead of within selling, general and administrative expenses. Additionally, we exclude amortization of certain acquired intangible assets, acquisition and integration related costs, and certain other items which include other charges or benefits resulting from transactions or events that are highly variable, significant in size, and that we do not believe are indicative of ongoing or future business operations. Adjusted gross margin is calculated as adjusted gross profit divided by total revenues.
- Adjusted cash burn: We calculate cash burn as the total change in cash, cash equivalents, and restricted cash adjusted to include the net change from purchases, sales, and maturities of marketable securities (excluding any interest receivable). Adjusted cash burn is calculated as cash burn further adjusted to exclude cash payments related to transactions or events that are highly variable, significant in size, and that we do not believe are indicative of ongoing or future business operations.
We believe that presentation of these non-GAAP financial measures provides supplemental information useful to investors in understanding our underlying operating results and trends. We use these non-GAAP financial measures to evaluate our operating performance in a manner that allows for meaningful period-to-period comparison and analysis of trends in our business and our competitors. We believe that presentation of these non-GAAP financial measures provides useful information to investors in assessing our operating performance within our industry and to allow comparability with the presentation of other companies in our industry.
The non-GAAP financial measures presented here should be considered in conjunction with, and not as a substitute for, the financial information presented in accordance with U.S. GAAP. For example, adjusted EBITDA excludes a number of expense items that are included in net loss and adjusted cash burn excludes certain actual cash payments. As a result, positive adjusted EBITDA or positive adjusted cash burn may be achieved even where we record a significant net loss or reduction in our cash and marketable securities balances in accordance with U.S. GAAP.
Investors are encouraged to review the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures set forth in the tables captioned “Reconciliation of GAAP to Non-GAAP Financial Measures” in the section below.
Additionally, we make certain forward-looking statements about our future financial performance that include non-GAAP financial measures, which are difficult to predict for future periods because the nature of the adjustments pertains to events that have not yet occurred. We do not forecast many of the excluded items for internal use and therefore information reconciling forward-looking non-GAAP financial measures to U.S. GAAP financial measures is not available without unreasonable effort and is not provided. The occurrence, timing, and amount of any of the items excluded from U.S. GAAP to calculate non-GAAP financial measures could significantly impact our U.S. GAAP results.
QUANTERIX CORPORATION
|
|||||||
|
Three Months Ended March 31, |
||||||
|
2025 |
|
2024 |
||||
Net loss |
$ |
(20,504 |
) |
|
$ |
(11,163 |
) |
Interest income |
|
(3,267 |
) |
|
|
(3,948 |
) |
Income tax expense (benefit) |
|
(2,913 |
) |
|
|
180 |
|
Depreciation and amortization |
|
2,188 |
|
|
|
1,523 |
|
Stock-based compensation expense |
|
5,462 |
|
|
|
5,265 |
|
Acquisition and integration related costs (1) |
|
3,578 |
|
|
|
— |
|
Earnout recorded as compensation expense (2) |
|
3,744 |
|
|
|
— |
|
Changes in contingent consideration (3) |
|
379 |
|
|
|
— |
|
Adjusted EBITDA (non-GAAP) |
$ |
(11,333 |
) |
|
$ |
(8,143 |
) |
|
|
|
|
||||
Total revenues |
$ |
30,333 |
|
|
$ |
32,066 |
|
Adjusted EBITDA margin (non-GAAP) (adjusted EBITDA as a % of revenue) |
|
(37.4 |
)% |
|
|
(25.4 |
)% |
(1) |
Represents acquisition and integration costs directly related to the Company's business combinations. Acquisition costs include professional and consulting fees supporting due diligence, legal, and accounting activities to execute a transaction. Integration costs include third party and internal direct costs to integrate acquired companies, employees, and their customers. |
(2) |
Consists of the earnout recognized as compensation expense related to the Emission acquisition. |
(3) |
Consists of fair value adjustments for the contingent consideration liability related to the Emission acquisition. |
Reconciliation of Net Increase in Cash, Cash Equivalents, and Restricted Cash to Adjusted Cash Burn (non-GAAP)
|
|||||||
|
Three Months Ended March 31, |
||||||
|
2025 |
|
2024 |
||||
Net increase (decrease) in cash, cash equivalents, and restricted cash |
$ |
18,967 |
|
|
$ |
(128,760 |
) |
Effect of exchange rate changes on cash, cash equivalents, and restricted cash |
|
861 |
|
|
|
(380 |
) |
Net change in marketable securities |
|
(42,044 |
) |
|
|
109,738 |
|
Cash burn |
|
(22,216 |
) |
|
|
(19,402 |
) |
Adjustments: |
|
|
|
||||
Acquisition and integration related (1) |
|
12,090 |
|
|
|
— |
|
Restatement related (2) |
|
1,102 |
|
|
|
— |
|
Adjusted cash burn |
$ |
(9,024 |
) |
|
$ |
(19,402 |
) |
(1) |
Represents cash payments towards acquisition and integration related activities, including the purchase of a business (net of cash acquired). |
(2) |
Payment of costs associated with the restatement of previously issued financial statements that was completed at the end of 2024. |
QUANTERIX CORPORATION
|
|||||||
|
Three Months Ended March 31, |
||||||
|
2025 |
|
2024 |
||||
Gross profit |
$ |
16,415 |
|
|
$ |
18,548 |
|
Shipping and handling costs |
|
(1,577 |
) |
|
|
(2,142 |
) |
Amortization of acquired intangible assets (1) |
|
227 |
|
|
|
— |
|
Adjusted gross profit (non-GAAP) |
$ |
15,065 |
|
|
$ |
16,406 |
|
|
|
|
|
||||
Total revenues |
$ |
30,333 |
|
|
$ |
32,066 |
|
Gross margin (gross profit as % of total revenues) |
|
54.1 |
% |
|
|
57.8 |
% |
Adjusted gross margin (non-GAAP) (adjusted gross profit as % of total revenues) |
|
49.7 |
% |
|
|
51.2 |
% |
|
|
|
|
||||
Total operating expenses |
$ |
42,781 |
|
|
$ |
33,705 |
|
Shipping and handling costs |
|
(1,577 |
) |
|
|
(2,142 |
) |
Acquisition and integration related costs (2) |
|
(3,578 |
) |
|
|
— |
|
Earnout recorded as compensation expense (3) |
|
(3,744 |
) |
|
|
— |
|
Adjusted total operating expenses (non-GAAP) |
$ |
33,882 |
|
|
$ |
31,563 |
|
|
|
|
|
||||
Loss from operations |
$ |
(26,366 |
) |
|
$ |
(15,157 |
) |
Amortization of acquired intangible assets (1) |
|
227 |
|
|
|
— |
|
Acquisition and integration related costs (2) |
|
3,578 |
|
|
|
— |
|
Earnout recorded as compensation expense (3) |
|
3,744 |
|
|
|
— |
|
Adjusted loss from operations (non-GAAP) |
$ |
(18,817 |
) |
|
$ |
(15,157 |
) |
(1) |
Consists only of the amortization of intangible assets acquired in 2025. |
(2) |
Represents acquisition and integration costs directly related to the Company's business combinations. Acquisition costs include professional and consulting fees supporting due diligence, legal, and accounting activities to execute a transaction. Integration costs include third party and internal direct costs to integrate acquired companies, employees, and their customers. |
(3) |
Consists of the earnout recognized as compensation expense related to the Emission acquisition. |
About Quanterix
From discovery to diagnostics, Quanterix’s ultra-sensitive biomarker detection is driving breakthroughs only made possible through its unparalleled sensitivity and flexibility. The Company’s Simoa technology has delivered the gold standard for earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the Level of Quantification of conventional analog methods. Its industry-leading precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Quanterix has been a trusted partner of the scientific community for nearly two decades, powering research published in more than 3,400 peer-reviewed journals. Find additional information about the Billerica, Massachusetts-based company at https://www.quanterix.com or follow us on Twitter and LinkedIn.
IMPORTANT ADDITIONAL INFORMATION
In connection with the proposed acquisition of Akoya Biosciences, Inc. (“Akoya”) by Quanterix (the “Merger”), Quanterix will file with the U.S. Securities and Exchange Commission (the “SEC”) a post-effective amendment to its registration statement on Form S-4 (as amended, the “Registration Statement”), which will contain a preliminary proxy statement of Akoya and a preliminary prospectus of Quanterix (the “Proxy Statement/Prospectus”), and each of Quanterix and Akoya have, and may in the future, file with the SEC other relevant documents regarding the proposed transaction. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE REGISTRATION STATEMENT AND THE PROXY STATEMENT/PROSPECTUS CAREFULLY AND IN THEIR ENTIRETY AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC BY QUANTERIX AND AKOYA, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THOSE DOCUMENTS WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT QUANTERIX, AKOYA AND THE PROPOSED TRANSACTION. A definitive copy of the Proxy Statement/Prospectus will be mailed to Akoya stockholders when that document is final. Investors and security holders will be able to obtain the Registration Statement and the Proxy Statement/Prospectus, as well as other filings containing information about Quanterix and Akoya, free of charge from Quanterix or Akoya or from the SEC’s website when they are filed. The documents filed by Quanterix with the SEC may be obtained free of charge at Quanterix’s website, at www.quanterix.com, or by requesting them by mail at Quanterix Investor Relations, 900 Middlesex Turnpike, Billerica, MA 01821. The documents filed by Akoya with the SEC may be obtained free of charge at Akoya’s website, at www.akoyabio.com, or by requesting them by mail at Akoya Biosciences, Inc., 100 Campus Drive, 6th Floor, Marlborough, MA 01752, ATTN: Chief Legal Officer.
PARTICIPANTS IN THE SOLICITATION
Quanterix and Akoya and certain of their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from the stockholders of Akoya in respect of the proposed transaction. Information about Akoya’s directors and executive officers is available in the Proxy Statement/Prospectus and Amendment No. 1 to Akoya’s Annual Report on Form 10-K as filed with the SEC by Akoya on April 28, 2025, and other documents filed by Akoya with the SEC. Other information regarding the persons who may, under the rules of the SEC, be deemed participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, is contained in the Proxy Statement/Prospectus and other relevant materials to be filed with the SEC regarding the proposed transaction when they become available. Investors should read the definitive Proxy Statement/Prospectus carefully when it becomes available before making any voting or investment decisions. You may obtain free copies of these documents from Quanterix or Akoya as indicated above.
NO OFFER OR SOLICITATION
This communication shall not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval with respect to the Merger, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the U.S. Securities Act of 1933, as amended.
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
Statements included in this press release which are not historical in nature or do not relate to current facts are intended to be, and are hereby identified as, forward-looking statements for purposes of the safe harbor provided by Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, among other things, statements about Quanterix’s future business outlook, operations, strategy and financial performance, including statements under the header “2025 Full Year Business Outlook,” and statements about the Merger.
Contacts
Media Contact:
Marissa Klaassen
(978) 488-1854
media@quanterix.com
Investor Relations Contact:
Joshua Young
(508) 846-3327
ir@quanterix.com
Read full story here
